智通财经网·2025-12-09 09:37Core Viewpoint - Morgan Stanley expresses that the inclusion of Eli Lilly's Tirzepatide in the national medical insurance directory is not entirely surprising and believes that Innovent Biologics (01801) can adopt flexible pricing strategies to respond to market changes [1] Group 1: Market Potential and Product Pipeline - The Chinese weight loss drug market is vast, providing ample space for the development of multiple blockbuster drugs [1] - Innovent Biologics is rated "Overweight" due to its product pipeline covering various fields including oncology, autoimmune diseases, metabolic diseases, and ophthalmology [1] - Short to medium-term investors may focus on the company's ability to license assets externally [1] Group 2: Sales Forecast and Target Price - Morgan Stanley predicts that by 2027, Innovent will have over ten products on the market, with sales potentially reaching 17 billion RMB [1] - A target price of 110 HKD is set for Innovent Biologics [1] Group 3: Stock Performance and Investor Sentiment - On October 8, Innovent Biologics' stock price fell by approximately 7%, compared to a 1.5% decline in the Hang Seng Healthcare Index (HSHCI) on the same day [1] - Investor concerns are linked to the recent announcement regarding the national medical insurance drug directory negotiations, particularly regarding the impact of Eli Lilly's Tirzepatide on the sales potential of Innovent's Mazdutide [1] - There are also worries that Innovent may need to implement greater-than-expected price reductions to include small molecule inhibitors in the medical insurance directory [1]